Premium
Clinical use of p‐proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein
Author(s) -
Henry Laurent,
Fabre Cécile,
Guiraud Isabelle,
Bastide Sophie,
FabbroPeray Pascale,
Martinez Jean,
LavabreBertrand Thierry,
Meunier Laurent,
Stoebner PierreEmmanuel
Publication year - 2013
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.27991
Subject(s) - proteasome , medicine , biomarker , melanoma , lactate dehydrogenase , univariate analysis , lymph node , oncology , pathology , cancer research , biology , multivariate analysis , enzyme , biochemistry
Plasmatic proteasome (p‐proteasome) has recently been described as a new marker for metastatic melanoma. The objective of this study was to compare the diagnostic and prognostic values of p‐proteasome with three other melanoma serological markers: S100B protein, melanoma inhibitory activity protein (MIA) and lactate dehydrogenase (LDH) in the plasma of 121 stage I–IV melanoma patients. Laboratory analyses were performed by standardized ELISA (p‐proteasome, MIA), immunoluminometric assay (S100B) and colorimetry (LDH). We found that all markers were relevant for discriminating metastatic from nonmetastatic patients but p‐proteasome displayed the highest diagnostic accuracy. P‐proteasome and S100B were the most sensitive (58.1%) and p‐proteasome and MIA the most specific (98.7 and 100%) in detecting metastatic disease. P‐proteasome and S100B had the highest area under receiver operating characteristics curve, 0.811 (95% CI: 0.725–0.897) and 0.822 (95% CI: 0.738–0.906), respectively. These two markers were the best in detecting patients with lymph node metastases. S100B, MIA and LDH diagnostic accuracy was increased when these markers were combined with p‐proteasome. As shown with univariate analysis, shorter progression‐free and overall survival rates were significantly associated with elevated plasma levels of each markers. The multivariate Cox regression analysis identified p‐proteasome as the only independent predictor of a poorer progression‐free survival ( p = 0.030). In conclusion, this comparative study established that p‐proteasome quantification in combination with other melanoma biomarkers is an attractive approach for the biological follow‐up of melanoma patients.